DCT

1:26-cv-00855

MyoKardia Inc v. Micro Labs Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00855, D. Del., 07/14/2026
  • Venue Allegations: Venue is alleged to be proper for Micro Labs Ltd., an Indian corporation, based on its being subject to personal jurisdiction in the district. For Micro Labs USA, Inc., venue is also based on its being subject to personal jurisdiction. The complaint further notes that the Defendants have represented that they do not object to personal jurisdiction or venue in Delaware for this action.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiffs' drug Camzyos® (mavacamten) constitutes an act of infringement of two patents covering the compound and its method of use.
  • Technical Context: The technology involves small molecule pyrimidinedione compounds, specifically the cardiac myosin inhibitor mavacamten, used to treat obstructive hypertrophic cardiomyopathy, a heritable disease of the heart muscle.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following a notice letter from Micro Labs, dated June 5, 2026, informing Plaintiffs of its ANDA filing. The ANDA includes a "Paragraph IV" certification, asserting that Plaintiffs' patents are invalid, unenforceable, or will not be infringed by the proposed generic product. This lawsuit, filed within 45 days of the notice, triggers an automatic 30-month stay on the FDA's approval of the generic product.

Case Timeline

Date Event
2013-06-21 Priority Date for RE'050 Patent and '883 Patent
2017-03-07 '883 Patent Issue Date
2024-07-23 RE'050 Patent Issue Date
2026-06-05 Micro Labs sends ANDA Notice Letter to Plaintiffs
2026-07-14 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissue Patent No. 50,050 - Pyrimidinedione Compounds

  • Patent Identification: U.S. Reissue Patent No. RE50,050, issued July 23, 2024.

The Invention Explained

  • Problem Addressed: The patent addresses genetic hypertrophic cardiomyopathy (HCM), a myocardial disease caused by mutations in sarcomere (heart muscle) proteins '050 Patent, col. 1:21-28 The background section notes that existing medical therapies for HCM are limited to symptom management and do not address the underlying cause of the disease, which is a disruption in normal sarcomere function RE'050 Patent, col. 2:4-28
  • The Patented Solution: The invention provides a class of novel pyrimidine dione compounds, including mavacamten, which act as cardiac myosin inhibitors RE'050 Patent, abstract These compounds are designed to reduce excessive contractility by stabilizing a specific conformation of beta cardiac myosin, thereby decreasing the proportion of myosin molecules available for the muscle contraction "powerstroke" RE'050 Patent, col. 3:24-34 This mechanism is intended to improve cardiac relaxation and elasticity RE'050 Patent, col. 3:35-44
  • Technical Importance: This technology represents a targeted therapeutic approach that modulates the fundamental biomechanics of the heart muscle at the molecular level, offering a potential disease-modifying treatment for HCM rather than purely symptomatic relief RE'050 Patent, col. 2:23-28

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the RE'050 patent, including at least claim 20 Compl. ¶41
  • The complaint alleges that claim 20 specifically covers the mavacamten compound Compl. ¶33
  • The complaint does not identify the independent claim from which claim 20 depends or provide its elements.

U.S. Patent No. 9,585,883 - Pyrimidinedione Compounds

  • Patent Identification: U.S. Patent No. 9,585,883, issued March 7, 2017.

The Invention Explained

  • Problem Addressed: The '883 patent addresses the same problem as the RE'050 patent: the lack of effective, disease-modifying treatments for hypertrophic cardiomyopathy (HCM) '883 Patent, col. 1:21 - col. 2:28
  • The Patented Solution: The patent claims methods of treating HCM by administering an effective amount of the pyrimidinedione compounds described in the specification, including mavacamten '883 Patent, abstract '883 Patent, col. 9:51-56 The therapeutic mechanism is identical to that described for the RE'050 patent, involving the inhibition of cardiac myosin to reduce hypercontractility and improve cardiac relaxation '883 Patent, col. 3:24-34
  • Technical Importance: The '883 patent protects the specific use of the novel compounds for treating HCM, providing a layer of protection focused on the therapeutic application of the core chemical invention.

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the '883 patent, including at least claim 18 Compl. ¶¶53-57 Claim 1 is the independent claim from which claim 18 depends.
  • The essential elements of independent claim 1 are:
    • A method of treating hypertrophic cardiomyopathy (HCM),
    • comprising administering to a subject in need thereof an effective amount of a compound having the formula [a specific chemical structure is depicted] or a pharmaceutically acceptable salt thereof.
  • Dependent claim 18 narrows the compound to (S)-3-isopropyl-6-((1-phenylethyl)amino)pyrimidine-2,4(1H,3H)-dione, which is mavacamten '883 Patent, col. 10:1-4

III. The Accused Instrumentality

Product Identification

  • Micro Labs's ANDA Product, which is a proposed generic version of Camzyos® (mavacamten) capsules in 2.5 mg, 5 mg, 10 mg, and 15 mg dosages Compl. ¶2

Functionality and Market Context

  • The active ingredient of the accused product is mavacamten, which is a cardiac myosin inhibitor Compl. ¶27
  • The product is intended for the same therapeutic use as the branded drug Camzyos®, which is to treat adults with obstructive hypertrophic cardiomyopathy Compl. ¶27 Compl. ¶28
  • The complaint alleges that *Myokardia Inc v. Micro Labs Ltd* seeks FDA approval to manufacture, use, sell, and import this generic product into the U.S. market prior to the expiration of the patents-in-suit Compl. ¶2

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed claim chart for the RE'050 patent. It makes the conclusory allegation that "Micro Labs's ANDA Product is covered by at least claim 20 of the RE'050 patent" Compl. ¶37 The primary dispute for this patent will likely center on validity, as infringement is typically straightforward when a generic product contains the identical active pharmaceutical ingredient as the patented compound.

'883 Patent Infringement Allegations

The infringement theory for the '883 patent is that the proposed labeling for Micro Labs's ANDA Product will instruct physicians and patients to administer the drug for the treatment of obstructive hypertrophic cardiomyopathy, thereby inducing infringement of the patented method Compl. ¶57 Compl. ¶61

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating hypertrophic cardiomyopathy (HCM) The proposed labeling for the ANDA product will direct its use for treating obstructive hypertrophic cardiomyopathy, the approved indication for the reference listed drug, Camzyos®. ¶27; ¶57 col. 17:11-13
comprising administering to a subject in need thereof The proposed labeling will instruct that the ANDA Product be administered to patients diagnosed with the condition. ¶57; ¶61 col. 17:13-14
an effective amount of a compound having the formula... [wherein the compound is mavacamten per dependent claim 18] The ANDA Product contains mavacamten as its active pharmaceutical ingredient in specified dosages (2.5 mg, 5 mg, 10 mg, and 15 mg). ¶2; ¶27 col. 10:1-4

Identified Points of Contention

  • Validity Questions: The central dispute will likely be the validity of the asserted claims. Micro Labs has filed a Paragraph IV certification alleging the patents are invalid and/or unenforceable Compl. ¶55 This suggests Micro Labs will likely challenge the patents on grounds such as obviousness or lack of adequate written description.
  • Infringement Scope (Method Claim): For the '883 patent, a potential point of contention, although less likely in a standard generic case, could be whether the instructions on Micro Labs's proposed label meet every limitation of the asserted method claims, thus satisfying the requirements for inducement.

V. Key Claim Terms for Construction

  • The Term: "treating" (from claim 1 of the '883 Patent)
  • Context and Importance: The definition of "treating" is fundamental to the scope of the method-of-use claims. A narrow definition could allow a defendant to argue that its product, while providing some benefit, does not "treat" the condition as contemplated by the patent. Practitioners may focus on this term to dispute the scope of the claimed method.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification explicitly defines "treat," "treating," and "treatment" to "refer to any indicia of success in the treatment or amelioration of a pathology," including "diminishing of symptoms" '883 Patent, col. 6:47-53 This broad definition could encompass mere symptomatic relief.
    • Evidence for a Narrower Interpretation: The patent distinguishes the invention from prior art therapies that "do not address the fundamental, underlying cause of disease" '883 Patent, col. 2:5-7 A defendant could argue that "treating" should therefore be construed more narrowly to require addressing this underlying cause, such as by promoting "salutary ventricular remodeling" or reducing "interstitial myocardial fibrosis" as described elsewhere in the specification '883 Patent, col. 18:18-21 '883 Patent, col. 18:49-50

VI. Other Allegations

  • Indirect Infringement: Plaintiffs allege that Micro Labs will actively induce infringement of the '883 patent claims Compl. ¶61 The factual basis for this allegation is that Micro Labs's proposed product labeling will instruct medical professionals and patients to use the generic drug in a manner that directly infringes the patented method of treating HCM Compl. ¶57 The complaint also alleges that Micro Labs's activities will be done with knowledge of the patent and specific intent to infringe Compl. ¶61 For both patents, contributory infringement is alleged on the basis that the ANDA product is not a staple article of commerce and is not suitable for substantial non-infringing use Compl. ¶38 Compl. ¶58
  • Willful Infringement: The complaint does not explicitly plead "willful infringement." However, it alleges that Micro Labs has knowledge of the patents-in-suit and has "continued to assert its intent to manufacture, offer for sale, sell, distribute, and/or import" the accused product Compl. ¶42 Compl. ¶62 These allegations of pre-suit knowledge could form the basis for a later claim of willfulness should Micro Labs engage in commercial activity post-approval. The prayer for relief also seeks a declaration that the case is "exceptional" for the purpose of awarding attorneys' fees Prayer for Relief, ¶i

VII. Analyst's Conclusion: Key Questions for the Case

  • A central question will be one of patent validity: As is typical in ANDA litigation, the case will likely turn on whether Micro Labs can prove by clear and convincing evidence that the asserted claims of the RE'050 and '883 patents are invalid for reasons such as obviousness over the prior art or failure to meet the written description and enablement requirements of 35 U.S.C. § 112.
  • A secondary issue will be one of induced infringement: For the '883 method-of-use patent, a key evidentiary question will be whether the specific instructions and indications on Micro Labs's proposed FDA label are sufficient to demonstrate the specific intent required to induce infringement by medical providers and patients.
  • A final question will relate to claim scope: While the active ingredient appears to be identical, a potential dispute could arise regarding whether the specific form (e.g., salt, polymorph) of mavacamten used in Micro Labs's ANDA product falls within the scope of the term "compound" as construed from the language of the RE'050 patent's claims.
Loading Complaint